Compare · DCOY vs NVO
DCOY vs NVO
Side-by-side comparison of Decoy Therapeutics Inc. (DCOY) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DCOY and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $215.95B, about 80544.8x DCOY ($2.7M).
- Over the past year, DCOY is down 96.1% and NVO is down 29.3% - NVO leads by 66.8 points.
- DCOY has been more active in the news (6 items in the past 4 weeks vs 4 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 1 for DCOY).
- Company
- Decoy Therapeutics Inc.
- Novo Nordisk A/S
- Price
- $5.10-3.59%
- $48.78+1.22%
- Market cap
- $2.7M
- $215.95B
- 1M return
- -15.70%
- +2.89%
- 1Y return
- -96.12%
- -29.29%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2015
- News (4w)
- 6
- 4
- Recent ratings
- 1
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest DCOY
- SEC Form PRE 14A filed by Decoy Therapeutics Inc.
- SEC Form EFFECT filed by Decoy Therapeutics Inc.
- SEC Form 424B3 filed by Decoy Therapeutics Inc.
- SEC Form 8-K filed by Decoy Therapeutics Inc.
- Decoy Therapeutics Stockholders Elect Patricia Gauthier to Board of Directors
- SEC Form S-1 filed by Decoy Therapeutics Inc.
- 4 Sizzling Biotech and Healthcare Companies Reporting Strategic Milestones
- Decoy Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits
- Decoy Therapeutics, Inc. Announces Up to $21 Million Private Placement Financing
- SEC Form EFFECT filed by Decoy Therapeutics Inc.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S